FDA Guidance: Plausible Mechanism Framework for Individualized Genetic Therapies

Detected February 27th, 2026

Summary

The FDA has issued draft guidance outlining a plausible mechanism framework for developing individualized genetic therapies. This framework provides recommendations for generating substantial evidence of effectiveness and safety for these novel treatments. The comment period for this draft guidance closes on April 27, 2026.

View original document View source feed page

What changed

The FDA has released draft guidance titled "Considerations for Use of a Plausible Mechanism Framework to Develop Individualized Therapies to Target Specific Genetic Mutations." This document describes a framework intended to help developers of individualized therapies generate sufficient clinical safety and efficacy data, along with chemistry, manufacturing, and controls (CMC) data, to support product approval or licensure. The guidance focuses on evaluating nonclinical and clinical data to demonstrate that a product is safe, effective, and manufactured to regulatory quality standards for a specific indication.

This guidance is relevant for drug and biologics developers, particularly those working on gene therapies. While it is non-binding, it outlines the FDA's current thinking on how to support approval for these complex therapies. Regulated entities should review the framework and consider submitting comments by the deadline of April 27, 2026, to influence the final version of the guidance. Failure to align with these considerations could impact the successful development and approval pathway for individualized therapies.

Source document (simplified)

Search for FDA
Guidance Documents

Submit Comments by

04/27/2026

Submit Comments Online Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment on a draft guidance before it begins work on the final version of the guidance, submit either online or written comments on the draft guidance before the close date.

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2026-D-1256

Docket Number: FDA-2026-D-1256 Issued by: Guidance Issuing Office Center for Biologics Evaluation and Research Center for Drug Evaluation and Research The purpose of this guidance is to describe considerations for generating substantial evidence of effectiveness and evidence of safety for individualized therapies based on a plausible mechanism framework. The plausible mechanism framework outlines a set of recommendations to help developers of individualized therapies generate sufficient clinical safety and efficacy data to demonstrate that a drug or biological product is safe and effective for the intended use, and that the product can be manufactured to regulatory quality standards. These data are used to support approval or licensure of an individualized therapy for a specific indication. This includes a careful evaluation of the results of nonclinical and clinical data and chemistry, manufacturing, and controls (CMC) data necessary to support product quality.

Questions?

Contact Point Office of Communication, Outreach and Development (OCOD) Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave WO71-3128
Silver Spring, MD 20993-0002 ocod@fda.hhs.gov (800) 835-4709 (240) 402-8010